BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs episode artwork

EPISODE · Jun 17, 2025 · 10 MIN

BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs

from BiotechTV - News · host BiotechTV

He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short half-life. Plus, background on programs targeting MC1R, SSTR2, and FAP-α.

He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short half-life. Plus, background on programs targeting MC1R, SSTR2, and FAP-α.

NOW PLAYING

BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs

0:00 10:02

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 10 minutes long.

When was this BiotechTV - News episode published?

This episode was published on June 17, 2025.

What is this episode about?

He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short half-life. Plus, background on programs targeting MC1R, SSTR2, and FAP-α.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!